Analyst Price Targets — PASG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 21, 2026 12:04 pm | — | Oppenheimer | $15.00 | $6.08 | TheFly | Passage Bio price target lowered to $15 from $30 at Oppenheimer |
| April 21, 2026 10:52 am | — | Wedbush | $8.00 | $6.25 | TheFly | Passage Bio downgraded to Neutral from Outperform at Wedbush |
| April 21, 2026 8:26 am | Janani Sundararajan | Chardan Capital | $7.00 | $6.25 | TheFly | Passage Bio downgraded to Neutral from Buy at Chardan |
| January 19, 2022 12:00 am | Madhu Kumar | Goldman Sachs | $6.00 | $4.94 | Pulse 2.0 | Passage Bio Stock (PASG): $6 Price Target From Goldman Sachs |
Latest News for PASG
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PASG.
U.S. House Trading
No House trades found for PASG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.